Teva appoints Michael Hayden president of global research and development and chief scientific officer

Teva Pharmaceutical Industries Ltd. has announced that Dr. Michael R. Hayden will join the company as the president of global research and development and chief scientific officer. In this new role, Hayden will lead all research and development for Israel-based Teva, combining the efforts of two teams focused on the development of both brand and generic medicines.

Hayden is Killam professor of Medical Genetics at UBC, and Canada Research Chair in Human Genetics and Molecular Medicine.

For more information, visit: http://www.thestreet.com/story/11527187/1/teva-appoints-michael-hayden-as-president-of-global-research-and-development-and-chief-scientific-officer.html